Authors’ replyBMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c6340 (Published 09 November 2010) Cite this as: BMJ 2010;341:c6340
- Peter Jüni, professor and head of division12,
- Eveline Nüesch, research fellow12,
- Sven Trelle, senior research fellow12
- 1Institute of Social and Preventive Medicine, University of Bern, Switzerland
- 2CTU Bern, Bern University Hospital, Switzerland
Pelletier and colleagues question the exclusion of small studies,1 although we have recently shown that small studies often distort results of meta-analyses of osteoarthritis trials, particularly for glucosamine and chondroitin trials.2 The issues of different types of glucosamine and differences in the quality and bioequivalence of preparations were examined in figure 3 of our report, without evidence to suggest that either will explain our results.
Giacovelli and Rovati suggest several errors in our classification of trials,3 which we were unable to confirm after careful re-examination of our data. The apparent misclassification of the trial …